Silver Book Fact

It is estimated that proper treatment and monitoring of the eyes of diabetics could reduce new cases of diabetic retinopathy by 90%.

Tapp R, Shaw J, Harper C, P de Courten M, et al. The Prevalence of and Factors Associated with Diabetic Retinopathy in the Australian Population. Diabetes Care. 2003; 26(6): 1731-1737. http://care.diabetesjournals.org/content/26/6/1731

Reference

Title
The Prevalence of and Factors Associated with Diabetic Retinopathy in the Australian Population
Publication
Diabetes Care
Publication Date
2003
Authors
Tapp R, Shaw J, Harper C, P de Courten M, et al
Volume & Issue
Volume 26, Issue 6
Pages
1731-1737
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Lucentis to treat wet age-related macular degeneration (AMD)
    An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25%…  
  • Anti-VEGF Visual Improvement
    Nearly 50% of DME patients who received an anti-VEGF drug, experienced substantial visual improvement after a year of injections.  
  • Because the resource use and direct cost of glaucoma treatment and management increases as the disease severity worsens– from an average $623 per early-stage patient to $2,511 per late-stage patient–…  
  • After 9 years of tight blood pressure control, patients with type 2 diabetes had a 34% reduction in retinopathy progression and a 47% reduction in risk of visual acuity deterioration…  
  • Screening and treatment of diabetic retinopathy in type 2 diabetes patients produces annual savings of $247.9 million to the federal budget– in 1994 dollars.